Key statistics
As of last trade, Shanghai Junshi Biosciences Co Ltd (8SJ:FRA) traded at 1.19, 12.26% above the 52 week low of 1.06 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.17 |
---|---|
High | 1.19 |
Low | 1.17 |
Bid | 1.18 |
Offer | 1.26 |
Previous close | 1.17 |
Average volume | 0.00 |
---|---|
Shares outstanding | 985.69m |
Free float | 149.56m |
P/E (TTM) | -- |
Market cap | 22.93bn HKD |
EPS (TTM) | -2.16 HKD |
Data delayed at least 15 minutes, as of Sep 20 2024 08:59 BST.
More ▼
Announcements
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
- Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
- Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
- Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
More ▼